Deep phenotyping of chronic inducible urticaria
Part of Immune system & allergy, Skin clinical trials.
This study aims to better understand inducible urticaria (hives triggered by cold, pressure, or friction) and chronic spontaneous urticaria. Researchers will use skin tests to measure how different triggers affect your skin in detail.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You either need to be a healthy volunteer without any skin conditions, OR you have a doctor-confirmed diagnosis of symptomatic dermographism (SD), cold urticaria (ColdU), or moderate-to-severe chronic spontaneous urticaria (CSU) that has lasted at least 3 months and isn't well-controlled with antihistamines.
- If you have SD or ColdU, you must have a positive reaction to a specific skin test (FricTest or TempTest) at both the screening and baseline visits.
- If you have CSU, you must have negative results on both the skin-prick and friction tests at screening.
- You cannot have any other significant medical conditions, skin diseases, or be taking certain medications like oral steroids or omalizumab within a specific time before the study starts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different skin diseases to find markers that can help guide treatment. It tests new treatments for several conditions like eczema, psoriasis, and lupus, with the goal of personalizing care.
This trial tests a new drug, GTX-B001, in healthy people and those with a type of hives called chronic inducible urticaria (specifically cold-induced or scratch-induced hives). The goal is to see if it's safe and helps control symptoms that don't respond well to standard antihistamines.
This trial tests an experimental medicine for chronic hives (called chronic spontaneous urticaria). It is for people whose hives still bother them about once or twice a month despite daily treatment, and who do not have heart problems.
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
This trial tests a new oral medication for chronic spontaneous urticaria (chronic hives). It is a placebo-controlled study, meaning some participants will get the new drug and some will get a placebo (a pill with no active ingredient). The goal is to see if the new drug is safe and how well it works, possibly providing a new treatment option for those whose hives are not controlled by current antihistamines.
This study tests an experimental capsule (HS-10561) to see if it is safe and works for people with chronic spontaneous urticaria, which causes hives and itching without a clear trigger. If you have had hives for at least 6 months, you might be able to join.
Hear when a new Skin Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.